

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
 CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:41:56 ON 04 FEB 2003

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.47	1.47

FILE 'CAPLUS' ENTERED AT 12:46:04 ON 04 FEB 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:46:04 ON 04 FEB 2003
 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 12:46:04 ON 04 FEB 2003
 COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 12:46:04 ON 04 FEB 2003
 COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 12:46:04 ON 04 FEB 2003

FILE 'BIOSIS' ENTERED AT 12:46:04 ON 04 FEB 2003
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 12:46:04 ON 04 FEB 2003
 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s inhal? and (powder or particulat? or pellet)
 L1 32803 INHAL? AND (POWDER OR PARTICULAT? OR PELLETT)

=> s l1 and tiotropium
 L2 117 L1 AND TIOTROPIUM

=> s l2 and (average particle size)
 L3 12 L2 AND (AVERAGE PARTICLE SIZE)

=> s l3 and (chloride or bromide or iodide methanesulphonate or paratoluenesulphonate or (methyl sulphate))

L4 12 L3 AND (CHLORIDE OR BROMIDE OR IODIDE METHANESULPHONATE OR
PARATOLUENESULPHONATE OR (METHYL SULPHATE))

=> d 14 1-12 ibib abs

L4 ANSWER 1 OF 12 USPATFULL

ACCESSION NUMBER: 2003:24176 USPATFULL
TITLE: Pharmaceutical compositions based on anticholinergics,
corticosteroids and betamimetics
INVENTOR(S): Meade, Christopher J.M., Bingen, GERMANY, FEDERAL
REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC
OF
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Ingelheim, GERMANY,
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018019	A1	20030123
APPLICATION INFO.:	US 2002-173194	A1	20020617 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-130371	20010623
	US 2001-304148P	20010710 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1170	

AB The present invention relates to novel pharmaceutical compositions based
on anticholinergics, corticosteroids and betamimetics, processes for
preparing them and their use in the treatment of respiratory diseases.

L4 ANSWER 2 OF 12 USPATFULL

ACCESSION NUMBER: 2002:338027 USPATFULL
TITLE: Compounds for treating inflammatory diseases
INVENTOR(S): Disse, Bernd, Mainz, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193394	A1	20021219
APPLICATION INFO.:	US 2002-96810	A1	20020313 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-111843	20010313
	US 2001-281876P	20010405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	661	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of (1.alpha..2.beta.,4.beta..5.alpha..7.beta.)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4] nonane salts for preparing a pharmaceutical composition for the prevention and treatment of diseases associated with inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 12 USPATFULL

ACCESSION NUMBER: 2002:338026 USPATFULL
TITLE: Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
INVENTOR(S): Pairret, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Meade, Christopher J. M., Bingen, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193393	A1	20021219
APPLICATION INFO.:	US 2002-93240	A1	20020307 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-110772	20010307
	US 2001-281857P	20010405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1018	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors, processes for preparing them and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 12 USPATFULL

ACCESSION NUMBER: 2002:338025 USPATFULL
TITLE: Pharmaceutical compositions based on **tiotropium** salts of salts of salmeterol
INVENTOR(S): Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Nagel, Juergen, Bad Kreuznach, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193392	A1	20021219
APPLICATION INFO.:	US 2001-54567	A1	20011113 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10056104	20001113
	US 2000-251603P	20001206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 46

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 936

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition, comprising: (a) a **tiotropium** salt (1); and (b) a salmeterol salt (2), optionally in the form of the enantiomers, mixtures of enantiomers, or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient, and methods of treating respiratory diseases using such a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 12 USPATFULL

ACCESSION NUMBER: 2002:323179 USPATFULL

TITLE: Pharmaceutical compositions based on anticholinergics and endothelin antagonists

INVENTOR(S): Meade, Christopher J. M., Bingen, GERMANY, FEDERAL
REPUBLIC OF
Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC
OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002183347	A1	20021205
APPLICATION INFO.:	US 2002-100659	A1	20020318 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-113366	20010320
	US 2001-281874P	20010405 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 15

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 943

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based on anticholinergics and endothelin antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 12 USPATFULL

ACCESSION NUMBER: 2002:323126 USPATFULL

TITLE: Pharmaceutical compositions based on anticholinergics and corticosteroids

INVENTOR(S): Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC
OF
Meade, Christopher John Montague, Bingen, GERMANY,
FEDERAL REPUBLIC OF
Reichl, Richard, Gau-Algesheim, GERMANY, FEDERAL
REPUBLIC OF

Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002183292	A1	20021205	
APPLICATION INFO.:	US 2001-86145	A1	20011019	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 2000-10054042	20001031	
	DE 2000-10062712	20001215	
	US 2000-257220P	20001221	(60)
	US 2000-253613P	20001128	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising an anticholinergic and a
steroid, optionally together with a pharmaceutically acceptable
excipient, the anticholinergic and the steroid optionally in the form of
their enantiomers, mixtures of their enantiomers, their racemates, their
solvates, or their hydrates, processes for preparing them, and their use
in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 12 USPATFULL

ACCESSION NUMBER: 2002:301636 USPATFULL
TITLE: Pharmaceutical compositions based on anticholinergics
and NK1-receptor antagonists
INVENTOR(S): Pairet, Michel, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Bingen, GERMANY, FEDERAL REPUBLIC
OF
Meade, Christopher J. M., Bingen, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002169181	A1	20021114	
APPLICATION INFO.:	US 2002-92116	A1	20020306	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	DE 2001-DE111058	20010308	
	US 2001-281653P	20010405	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1338

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel pharmaceutical compositions based
on anticholinergics and NK.sub.1-receptor antagonists, processes for

preparing them and their use in the treatment of respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 12 USPATFULL

ACCESSION NUMBER: 2002:273413 USPATFULL

TITLE: Pharmaceutical compositions containing
tiotropium salts and antihistamines and their
use

INVENTOR(S): Pairet, Michel, Stromberg, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Ingelheim, GERMANY, FEDERAL
REPUBLIC OF
Meade, Christopher John Montague, Bingen, GERMANY,
FEDERAL REPUBLIC OF
Schmelzer, Christel, Ingelheim, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151541	A1	20021017
APPLICATION INFO.:	US 2001-7182	A1	20011019 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10054042	20001031
	DE 2001-138272	20010810
	US 2000-253613P	20001128 (60)
	US 2001-314599P	20010824 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 1074

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising a **tiotropium** salt; and
an antihistamine, optionally together with a pharmaceutically acceptable
excipient, the **tiotropium** salt and the antihistamine
optionally in the form of their enantiomers, mixtures of their
enantiomers, their racemates, their solvates, or their hydrates,
processes for preparing them, and their use in the treatment of
respiratory tract diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 12 USPATFULL

ACCESSION NUMBER: 2002:227675 USPATFULL

TITLE: Solid peptide preparations for **inhalation** and
their preparation

INVENTOR(S): Lizio, Rosario, Buttelborn, GERMANY, FEDERAL REPUBLIC
OF
Damm, Michael, Rodermark, GERMANY, FEDERAL REPUBLIC OF
Sarlikiotis, Werner, Peania, GREECE
Wolf-Heuss, Elisabeth, Mosbach, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122826	A1	20020905

APPLICATION INFO.: US 2001-944060 A1 20010831 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10043509	20000901
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Goodwin Procter L.L.P., 599 Lexington Avenue, 40th floor, New York, NY, 10022	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	764	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers .	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 12 USPATFULL
ACCESSION NUMBER: 2002:227622 USPATFULL
TITLE: Pharmaceutical compositions based on anticholinergics and dopamine agonists
INVENTOR(S): Pairet, Michel, Stromberg, GERMANY, FEDERAL REPUBLIC OF
Pieper, Michael P., Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Montague Meade, Christopher J., Bingen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122773	A1	20020905
APPLICATION INFO.:	US 2001-27662	A1	20011220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-DE10063957	20001220
	US 2000-257221P	20001221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1016	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to novel pharmaceutical compositions based on anticholinergics and dopamine agonists, processes for preparing them and their use in the treatment of respiratory tract diseases.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 12 USPATFULL
ACCESSION NUMBER: 2002:205842 USPATFULL
TITLE: **Inhalable powder** containing **tiotropium**
INVENTOR(S): Bechtold-Peters, Karoline, Biberach, GERMANY, FEDERAL REPUBLIC OF
Walz, Michael, Bingen, GERMANY, FEDERAL REPUBLIC OF

Boeck, Georg, Mainz, GERMANY, FEDERAL REPUBLIC OF
Doerr, Rolf, Ober-Olm, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110529	A1	20020815
APPLICATION INFO.:	US 2001-975418	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-DE10050635	20001012
	US 2000-252683P	20001122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	561	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to powdered preparations containing **tiotropium** for **inhalation**, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 12 USPATFULL

ACCESSION NUMBER: 2002:198239 USPATFULL
TITLE: Process for preparing **powder** formulations
INVENTOR(S): Walz, Michael, Bingen, GERMANY, FEDERAL REPUBLIC OF
Boeck, Georg, Mainz, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106332	A1	20020808
APPLICATION INFO.:	US 2001-977911	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-DE10050635	20001012
	DE 2001-DE138022	20010810
	US 2000-252683P	20001122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	650	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a new process for producing powdered preparations for **inhalation**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAPLUS
NEWS	23	May 27	CAPLUS super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004
NEWS	EXPRESS		MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	INTER		General Internet Information
NEWS	LOGIN		Welcome Banner and News Items
NEWS	PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004

=> le caplus uspatful europatful japio medline biosis embase
LE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 16:10:45 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 16:10:45 ON 10 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))
L1 60 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s l1 and (particle# or particulate#)
L2 29 L1 AND (PARTICLE# OR PARTICULATE#)

=> s l2 and powder?
L3 19 L2 AND POWDER?

=> s l3 and capsule?
L4 13 L3 AND CAPSULE?

=> s l4 and (COPD or asthma)
L5 5 L4 AND (COPD OR ASTHMA)

=> s l5 and (method or process) and (making or preparation or manufacture)
6 FILES SEARCHED...
L6 2 L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MANUFACTURE)

=> d l6 1-2 IBIB ABA
'ABA' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ABS

NO VALID FORMATS ENTERED FOR FILE 'EUROPATFULL'

In a multifile environment, each file must have at least one valid format requested. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):AB

L6 ANSWER 1 OF 2 USPATFULL on STN

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> S

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):L6 ibib ab

MISSING OPERATOR L6 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l6 1-2 IBIB AB

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;
YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP
PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, JP
PATENT ASSIGNEE NO: 435424
AGENT: Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675 Muenchen, DE
AGENT NUMBER: 100401
OTHER SOURCE: MEPA2004039 EP 1417975 A1 0322
SOURCE: Wila-EPZ-2004-H20-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PATENT INFORMATION:
PATENT NO KIND DATE

EP 1417975 A1 20040512
'OFFENLEGUNGS' DATE: 20040512
APPLICATION INFO.: EP 2002-747707 20020722

PRIORITY APPLN. INFO.: JP 2001-2001222148 20010723
 JP 2001-2001239895 20010807
 JP 2002-2002056449 20020301
 RELATED DOC. INFO.: WO 02-JP7385 020722 INTAKZ
 WO 2003009872 030206 INTPNR

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
 L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)
 L3 19 S L2 AND POWDER?
 L4 13 S L3 AND CAPSULE?
 L5 5 S L4 AND (COPD OR ASTHMA)
 L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

=> d 15 1-5

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:757705 CAPLUS
 DN 139:265796
 TI Preparation of micronized crystalline tiotropium bromide
 monohydrate and formulation as inhalant to treat asthma
 and COPD
 IN Bender, Helmut; Graebner, Hagen; Schindler, Konrad; Trunk, Michael Josef
 Friedrich; Walz, Michael
 PA Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,				
	MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				
	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,				
	NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,				
	ML, MR, NE, SN, TD, TG				
	DE 10212264	A1	20031002	DE 2002-10212264	20020320
	US 2004002510	A1	20040101	US 2003-385175	20030310
PRAI	DE 2002-10212264	A	20020320		
	US 2002-413129P	P	20020924		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:368320 CAPLUS
DN 136:374855
TI Inhalant compositions containing tiotropium salts and
salmeterol salts
IN Schmelzer, Christel; Nagel, Juergen
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10056104	A1	20020523	DE 2000-10056104	20001113
	AU 2002027910	A5	20020521	AU 2002-27910	20011109
	EP 1335728	A1	20030820	EP 2001-989446	20011109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001015226	A	20031007	BR 2001-15226	20011109
	EE 200300228	A	20031015	EE 2003-228	20011109
	JP 2004513146	T2	20040430	JP 2002-540737	20011109
	US 2002193392	A1	20021219	US 2001-54567	20011113
	NO 2003002111	A	20030708	NO 2003-2111	20030512
PRAI	DE 2000-10056104	A	20001113		
	US 2000-251603P	P	20001206		
	WO 2001-EP12962	W	20011109		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:689613 CAPLUS
DN 136:390861
TI Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity
AU Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.
CS Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA
SO Journal of Aerosol Medicine (2001), 14(3), 309-315
CODEN: JAEMEP; ISSN: 0894-2684
PB Mary Ann Liebert, Inc.
DT Journal
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 USPATFULL on STN
AN 2001:75378 USPATFULL
TI Methods and compositions for the prevention of tolerance to medications
IN Ahmed, Tahir, Coral Gables, FL, United States

PA Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)
 PI US 6235725 B1 20010522
 AI US 1999-362540 19990728 (9)
 PRAI US 1998-106507P 19981030 (60)
 DT Utility
 FS Granted
 LN.CNT 985
 INCL INCLM: 514/056.000
 INCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000
 NCL NCLM: 514/056.000
 NCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000
 IC [7]
 ICM: A61K031-70
 EXF 514/53; 514/54; 514/56; 514/653; 514/826; 514/23
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1417975 EUROPATFULL ED 20040513 EW 200420 FS OS
 TIEN REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.
 TIDE MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.
 TIFR MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.
 IN MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
 KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
 KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
 MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP
 PA ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, JP
 SO Wila-EPZ-2004-H20-T1b
 DS R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI
 PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
 PI EP 1417975 A1 20040512
 OD 20040512
 AI EP 2002-747707 20020722
 PRAI JP 2001-2001222148 20010723
 JP 2001-2001239895 20010807
 JP 2002-2002056449 20020301
 RLI WO 02-JP7385 020722 INTAKZ
 WO 2003009872 030206 INTPNR
 IC ICM A61K045-00
 ICS A61K031-559 C07D207-24 C07D207-27 C07D263-24
 C07C405-00 A61P019-08 A61P019-10

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

65.21

65.42

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2004 (20040604/UP).

=> file caplus uspatful japio europaftul biosis embase medline
'EUROPAFTUL' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):europatful

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.66

66.08

FILE 'CAPLUS' ENTERED AT 16:28:44 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'EUROPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'BIOSIS' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:28:44 ON 10 JUN 2004

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 16:10:45 ON 10 JUN 2004

L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)
L3 19 S L2 AND POWDER?
L4 13 S L3 AND CAPSULE?
L5 5 S L4 AND (COPD OR ASTHMA)
L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'
ENTERED AT 16:28:44 ON 10 JUN 2004

=> s l4 1-13

MISSING OPERATOR L4 1-13

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d 14 1-13 ibib abs

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757705 CAPLUS

DOCUMENT NUMBER: 139:265796

TITLE: Preparation of micronized crystalline
tiotropium bromide monohydrate and
formulation as **inhalant** to treat asthma and
COPD

INVENTOR(S): Bender, Helmut; Graebner, Hagen; Schindler, Konrad;
Trunk, Michael Josef Friedrich; Walz, Michael

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10212264	A1	20031002	DE 2002-10212264	20020320
US 2004002510	A1	20040101	US 2003-385175	20030310
PRIORITY APPLN. INFO.:			DE 2002-10212264 A	20020320
			US 2002-413129P P	20020924
AB	The invention relates to a micronized crystalline (1alpha, 2beta, 4beta, 5alpha, 7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane bromide, methods for the production thereof, and the use thereof for producing a medicament, particularly for producing a medicament having an anticholinergic effect. The preparation of tiotropium bromide monohydrate microcrystals includes the solution of tiotropium bromide in water, heating, clarification with active carbon, filtration and slow crystallization followed by micronization in an air jet mill under nitrogen atmospheric and exposing the micronized crystals to water vapor. Parameters of the monocline crystals are given. Micronized crystalline tiotropium bromide monohydrate is formulated to encapsulated inhalation powder and used to treat asthma and COPD. Thus inhalation capsules contained (mg): micronized tiotropium bromide 0.0225; lactose monohydrate (200 M) 5.2025; lactose monohydrate (5 µm) 0.2750; hard gelatin capsules 49.0.			
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:889143 CAPLUS

DOCUMENT NUMBER: 137:358198

TITLE: Stable **powder** inhalation dosage formulation

INVENTOR(S): Etzler, Frank M.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: U.S., 6 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482429	B1	20021119	US 2001-885349	20010620
WO 2003000240	A2	20030103	WO 2002-US18406	20020611
WO 2003000240	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1401409	A2	20040331	EP 2002-732063	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-885349 A 20010620
 WO 2002-US18406 W 20020611

AB An insufflation for the administration of a drug, e.g., ipratropium bromide, albuterol sulfate or **tiotropium bromide**, into a body cavity is described where the carrier for the drug is a finely divided **powder** selected from the group consisting of myoinositol, mannitol and cellobiose. For example, the cellobiose blend with ipratropium bromide which was inhaled from **capsules** into Aerobreather at 20, 40 and 60 L/min has a lower mean **particle** size than the lactose blend, which is the opposite of the **particle** sizing results from the Aerosizer. The peaks of the distributions for the cellobiose blend were shifted to lower **particle** sizes than the lactose blend at all inhalation rates. The difference could reflect differences in adhesion strength, **particle** size distribution or size selection of retained **particles**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:695761 CAPLUS

DOCUMENT NUMBER: 137:237718

TITLE: **Inhalant** compositions containing anticholinergics and PDE IV inhibitors

INVENTOR(S): Meade, Christopher John Montague; Pairet, Michel; Pieper, Michael Paul

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069945	A2	20020912	WO 2002-EP1988	20020226
WO 2002069945	A3	20030130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10110772 A1 20020912 DE 2001-10110772 20010307
 EP 1372649 A2 20040102 EP 2002-727329 20020226
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: DE 2001-10110772 A 20010307
 WO 2002-EP1988 W 20020226

OTHER SOURCE(S): MARPAT 137:237718

AB The invention relates to drug compns. based on anticholinergics and PDE IV inhibitors, to methods for their production, and to their use as inhalants for the treatment of respiratory tract diseases. Thus an inhalation powder was composed of capsules that contained (µg/capsule): tiotropium bromide 21.7; AWD-12-281 200; lactose 4778.3.

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:487380 CAPLUS

DOCUMENT NUMBER: 137:68157

TITLE: Inhalant compositions containing anticholinergics and dopamine agonists
 INVENTOR(S): Pairret, Michel; Pieper, Michael Paul; Meade, Christopher John Montague

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049624	A2	20020627	WO 2001-EP14568	20011212
WO 2002049624	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10063957	A1	20020627	DE 2000-10063957	20001220
AU 2002035767	A5	20020701	AU 2002-35767	20011212
EP 1345626	A2	20030924	EP 2001-985868	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004516264	T2	20040603	JP 2002-550966	20011212
US 2002122773	A1	20020905	US 2001-27662	20011220
PRIORITY APPLN. INFO.:			DE 2000-10063957 A	20001220
			US 2000-257221P P	20001221
			WO 2001-EP14568 W	20011212

AB The invention relates to novel pharmaceutical compns. based on anticholinergic agents and dopamine agonists, a method for the production of the compns. and the use of the same for the treatment of respiratory tract diseases. Thus an inhalation powder contained per capsule (µg): tiotropium bromide 21.7; viozan 270; lactose 4708.3.

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:465799 CAPLUS
DOCUMENT NUMBER: 137:37667
TITLE: **Inhalant** compositions containing
anticholinergics and ciclesonide corticosteroid
INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,
Christopher John Montague
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047668	A2	20020620	WO 2001-EP14579	20011212
WO 2002047668	A3	20020829		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002031691	A5	20020624	AU 2002-31691	20011212
EP 1349549	A2	20031008	EP 2001-991827	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004515528	T2	20040527	JP 2002-549242	20011212
PRIORITY APPLN. INFO.:			DE 2000-10062712 A	20001215
			DE 2000-10054042 A	20001031
			US 2000-253613P P	20001128
			US 2000-257220P P	20001221
			WO 2001-EP14579 W	20011212

AB The invention relates to novel medicament compns. based on anticholinesterase drugs and on ST-126, to methods for their production, and to their use in treating respiratory tract diseases. Thus an inhalation **powder** contained per **capsule** (μ g): **tiotropium bromide** x H₂O 22.5; ciclesonide 250; lactose 4727.5.

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:465798 CAPLUS
DOCUMENT NUMBER: 137:52368
TITLE: **Inhalant** compositions containing
anticholinergics and ST-126 corticosteroid
INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,
Christopher John Montague
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047667	A2	20020620	WO 2001-EP14567	20011212
WO 2002047667	A3	20021024		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10062712 A1 20020620 DE 2000-10062712 20001215
US 2002183292 A1 20021205 US 2001-86145 20011019
AU 2002024926 A5 20020624 AU 2002-24926 20011212

PRIORITY APPLN. INFO.: DE 2000-10062712 A 20001215
DE 2000-10054042 A 20001031
US 2000-253613P P 20001128
US 2000-257220P P 20001221
WO 2001-EP14567 W 20011212

AB The invention relates to novel medicament compns. based on
anticholinesterase drugs and on ST-126 corticosteroid, to methods for
their production, and to their use in treating respiratory tract diseases.
Thus an inhalation **powder** contained per **capsule**
(µg): **tiotropium bromide** x H₂O 22.5; ST-126 250;
lactose 4727.5.

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:368320 CAPLUS

DOCUMENT NUMBER: 136:374855

TITLE: **Inhalant** compositions containing
tiotropium salts and salmeterol salts

INVENTOR(S): Schmelzer, Christel; Nagel, Juergen

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
NO 2003002111	A	20030708	NO 2003-2111	20030512

PRIORITY APPLN. INFO.: DE 2000-10056104 A 20001113
US 2000-251603P P 20001206
WO 2001-EP12962 W 20011109

AB The invention relates to novel drug compns. based on **tiotropium**

salts and on salmeterol salts, a method for their production and their use for treating respiratory conditions. Thus an inhalation **powder** contained per **capsule** (μg): **tiotropium bromide** 10.8; salmeterol x 1/2 H₂SO₄ 27.9; Lactose 4961.3.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:353268 CAPLUS

DOCUMENT NUMBER: 136:374832

TITLE: **Inhalant** compositions containing anticholinergics and corticosteroids

INVENTOR(S): Pairat, Michel; Pieper, Michael Paul; Meade, Christopher John Montague; Reichl, Richard; Schmelzer, Christel

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036106	A2	20020510	WO 2001-EP12511	20011023
WO 2002036106	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002151541	A1	20021017	US 2001-7182	20011019
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002010575	A5	20020515	AU 2002-10575	20011023
EP 1333830	A2	20030813	EP 2001-978463	20011023
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004512359	T2	20040422	JP 2002-538918	20011023
US 2002137764	A1	20020926	US 2001-40196	20011025
US 2003181478	A1	20030925	US 2003-395777	20030324

PRIORITY APPLN. INFO.:
DE 2000-10054042 A 20001031
DE 2000-10062712 A 20001215
US 2000-253613P P 20001128
US 2000-257220P P 20001221
DE 2001-10138272 A 20010810
US 2001-314599P P 20010824
WO 2001-EP12511 W 20011023
US 2001-40196 B1 20011025

AB The invention relates to novel drug compns. based on anticholinergics and corticosteroids, a method for their production and their use for treating respiratory conditions. Thus an inhalation **powder** contained per **capsule** (μg): **tiotropium bromide** 21.7; budesonide 200; Lactose 4778.3.

L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:689613 CAPLUS

DOCUMENT NUMBER: 136:390861

TITLE: Effective delivery of **particles** with the HandiHaler dry **powder** inhalation system over

a range of chronic obstructive pulmonary disease severity

AUTHOR(S): Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.

CORPORATE SOURCE: Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA

SOURCE: Journal of Aerosol Medicine (2001), 14(3), 309-315
CODEN: JAEMEP; ISSN: 0894-2684

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The HandiHaler is a dry powder breath activated inhaler system developed for inhalation therapy for patients with airway disease. Its operation is based on the evacuation of powder from a pierced capsule. We sought to document the inspiratory flow rates attained by patients inspiring through the HandiHaler with various degrees of airflow limitation. Subjects with stable chronic obstructive pulmonary disease (COPD) were the study's population. An in vitro study of fine particle dose was conducted using an Andersen Cascade Impactor to assess medication delivery at low inspiratory flow rates. Subsequently, an in vivo study was conducted to determine inspiratory flow rates in patients with COPD as measured through a pneumotach with a custom coupler device with and without the HandiHaler. Patients were classified into three approx. equal groups of spirometric severity ranging from mild (46-65% predicted normal forced expiratory volume in 1 s [FEV1]), to moderate (28-45%) to severe ($\leq 27\%$). The in vitro study indicated delivery of medication at flow rates as low as 20 L/min. Twenty-six men completed the in vivo study (age 66.9 ± 10.9 yr, FEV1 = 1.02 ± 0.451). The median peak inspiratory flow rates attained in the mild (n = 8), moderate (n = 10), and severe (n = 8) categories were 45, 45.6, and 35.4 L/min resp. The min. peak inspiratory flow rates in the three groups were 28.2, 21.6 and 20.4 L/min. The HandiHaler device effectively delivers particles to the lung over a wide range of airflow limitation in patients with COPD.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators.

More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL
TITLE: Supercritical fluid extraction of mould lubricant from hard shell **capsules**
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States
Saim, Said, New Milford, CT, United States
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled **capsules** and dry, **powdered** pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co.,

Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun,
 Osaka 618-8585, JP;
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP;
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP;
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP
 PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome,
 Chuo-ku, Osaka-shi, Osaka 541-8526, JP
 PATENT ASSIGNEE NO: 435424
 AGENT: Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675
 Muenchen, DE
 AGENT NUMBER: 100401
 OTHER SOURCE: MEPA2004039 EP 1417975 A1 0322
 SOURCE: Wila-EPZ-2004-H20-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;
 Verfahren in Englisch
 DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R
 ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R
 MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R
 MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale
 Anmeldung)
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 1417975	A1	20040512
'OFFENLEGUNGS' DATE:			20040512
APPLICATION INFO.:	EP 2002-747707		20020722
PRIORITY APPLN. INFO.:	JP 2001-2001222148		20010723
	JP 2001-2001239895		20010807
	JP 2002-2002056449		20020301
RELATED DOC. INFO.:	WO 02-JP7385	020722	INTAKZ
	WO 2003009872	030206	INTPNR

L4 ANSWER 13 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN
 PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET
 ACCESSION NUMBER: 1391200 EUROPATFULL EW 200409 FS OS
 TITLE: DRUG PREPARATIONS.
 ARZNEIMITTEL.
 PREPARATIONS DE MEDICAMENTS.
 INVENTOR(S): ONUKI, Yoichi, 2-31-7, Nakadai, Narita-shi, Chiba
 286-0015, JP;
 OKADA, Minoru, 4-7-20, Kioroshihigashi, Inzai-shi, Chiba
 270-1323, JP;
 SAKAI, Hirotaka, 1-20-6, Yotsukaido, Yotsukaido-shi,
 Chiba 284-0005, JP;
 KANBE, Hideyoshi, 2-21-8, Mama, Ichikawa-shi, Chiba
 272-0826, JP;
 MIZUNO, Hiroyuki, 1-24-19, Hiyoshidai, Tomisato-machi,
 Inba-gun, Chiba 286-0201, JP;
 IMAMORI, Katsumi, 2521-86, Shimoshizushinden,
 Yotsukaido-shi, Chiba 284-0006, JP
 PATENT ASSIGNEE(S): SSP Co., Ltd., 12-4, Nihonbashi-hamacho 2-chome,
 Chuo-ku, Tokyo 103-8481, JP
 PATENT ASSIGNEE NO: 2557581
 AGENT: Hartz, Nikolai, Waechtershaeuser & Hartz,
 Patentanwaelte, Weinstrasse 8, 80333 Muenchen, DE

AGENT NUMBER: 85663
 OTHER SOURCE: MEPA2004017 EP 1391200 A1 0014
 SOURCE: Wila-EPZ-2004-H09-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;
 Verfahren in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R
 GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R
 SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale
 Anmeldung)
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 1391200	A1	20040225
'OFFENLEGUNGS' DATE:			20040225
APPLICATION INFO.:	EP 2002-726486		20020524
PRIORITY APPLN. INFO.:	JP 2001-2001156853		20010525
RELATED DOC. INFO.:	WO 200JP2005041	020524	INTAKZ
	WO 2002096405	021205	INTPNR

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1	60 S	INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2	29 S	L1 AND (PARTICLE# OR PARTICULATE#)
L3	19 S	L2 AND POWDER?
L4	13 S	L3 AND CAPSULE?
L5	5 S	L4 AND (COPD OR ASTHMA)
L6	2 S	L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'
 ENTERED AT 16:28:44 ON 10 JUN 2004

=> file uspatful

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	63.51	129.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

FILE 'USPATFULL' ENTERED AT 16:45:49 ON 10 JUN 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Jun 2004 (20040610/PD)
 FILE LAST UPDATED: 10 Jun 2004 (20040610/ED)
 HIGHEST GRANTED PATENT NUMBER: US6748598
 HIGHEST APPLICATION PUBLICATION NUMBER: US2004111778
 CA INDEXING IS CURRENT THROUGH 10 Jun 2004 (20040610/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Jun 2004 (20040610/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

>>> USPAT2 is now available. USPATFULL contains full text of the	<<<
>>> original, i.e., the earliest published granted patents or	<<<
>>> applications. USPAT2 contains full text of the latest US	<<<
>>> publications, starting in 2001, for the inventions covered in	<<<

```

>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))

```

1928 INHALANT
236 TIOTROPIUM
236 TIOTROPIUM
145139 BROMIDE
133 TIOTROPIUM BROMIDE
(TIOTROPIUM(W)BROMIDE)
236 TIOTROPIUM
145139 BROMIDE
156 MONHYDRATE
0 TIOTROPIUM BROMIDE MONHYDRATE
(TIOTROPIUM(W)BROMIDE(W)MONHYDRATE)

```

L7 13 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s l7 and (particle# or particulate#)

```

552872 PARTICLE#
156148 PARTICULATE#

```

L8 9 L7 AND (PARTICLE# OR PARTICULATE#)

=> s l2 and powder?

```

437594 POWDER?

```

L9 3 L2 AND POWDER?

=> d l9 1-3 ibib abs

L9 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:132947 USPATFULL

TITLE: Medical aerosol formulations

INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL
REPUBLIC OF
Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA,
02205

NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1

LINE COUNT: 986

AB Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.

L9 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL

TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules

INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States

Saim, Said, New Milford, CT, United States

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Page, Thurman K.
 ASSISTANT EXAMINER: Seidleck, Brian K.
 LEGAL REPRESENTATIVE: Raymond, Robert P., Stempel, Alan R., Devlin,
 Mary-Ellen M.
 NUMBER OF CLAIMS: 21
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 24 Drawing Figure(s); 12 Drawing Page(s)
 LINE COUNT: 1487
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Hard shelled capsules and dry, **powdered** pharmaceutical
 formulations are treated with supercritical fluids to remove impurities
 such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 1-9 ibib abs

L8 ANSWER 1 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 2004:132947 USPATFULL
 TITLE: Medical aerosol formulations
 INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL
 REPUBLIC OF
 Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	986	

AB Calcium salts, magnesium salts and zinc salts of palmitic acid and of
 stearic acid are suited for use as solid auxiliary agents for medical
 suspension aerosol formulations based on hydrofluoroalkanes. They
 improve, in particular, the suspension stability, the mechanical
 function of the dosing valve, the dosing precision, and the chemical
 stability of the active substance.

L8 ANSWER 2 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 2003:283185 USPATFULL
 TITLE: Nitrosated and nitrosylated compounds and compositions
 and their use for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Dover, MA, UNITED STATES
 Letts, L. Gordon, Dover, MA, UNITED STATES
 Renfro, H. Burt, Wellesley, MA, UNITED STATES
 Richardson, Stewart K., Ashford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199529	A1	20031023
APPLICATION INFO.:	US 2003-428936	A1	20030505 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-689851, filed on 13 Oct 2000, GRANTED, Pat. No. US 6579863 Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, GRANTED, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, GRANTED, Pat. No. US 5824669 Division of Ser. No. WO 1997-US4319, filed on 19 Mar 1997, PENDING

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Page(s)

LINE COUNT: 2520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.cndot.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:176162 USPATFULL

TITLE: Medicinal aerosol formulations

INVENTOR(S): Keller, Manfred, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF
Herzog, Kurt, Basel, SWITZERLAND
Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
Kraus, Holger, Rickenbach, SWITZERLAND
PATENT ASSIGNEE(S): Jago Research AG, Muttentz, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6585958	B1	20030701
	WO 2000006121		20000210
APPLICATION INFO.:	US 2001-744379		20010413 (9)
	WO 1999-CH337		19990722

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1998-1565	19980724
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Hartley, Michael G.	
ASSISTANT EXAMINER:	Haghighatian, M.	
LEGAL REPRESENTATIVE:	Selitto, Behr & Kim	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	995	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pressure-liquefied propellant mixture for aerosols, comprising

dinitrogen monoxide and a hydrofluoroalkane having 1 to 3 carbon atoms, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, makes possible an improvement in the wetting properties of pharmaceutically active compounds, whereby the formulation problems existing with hydrofluoroalkanes can be overcome with respect to suspension and solution aerosols and thus improved medicinal aerosol formulations can be obtained. With the aid of dinitrogen monoxide, it is also possible to influence the pressure and thus the **particle** size distribution specifically and, by displacement of oxygen from the hydrofluoroalkanes, to improve the storage stability of oxidation-sensitive active compounds. If desired, the propellant mixture can additionally contain carbon dioxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:161952 USPATFULL
 TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Waltham, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfro, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): Nitromed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
	-----	----	-----
PATENT INFORMATION:	US 6579863	B1	20030617
APPLICATION INFO.:	US 2000-689851		20001013 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, now patented, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Badio, Barbara P.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	2028		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.cndot.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL
 TITLE: Methods and compositions for the prevention of tolerance to medications
 INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL
TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States
Saim, Said, New Milford, CT, United States
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:42141 USPATFULL
 TITLE: Nitrosated and nitrosylated compounds, and compositions and their use for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Dover, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfroe, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37116	E1	20010327
	US 5824669		19981020 (Original)
APPLICATION INFO.:	US 1998-219476		19981223 (9)
	US 1996-620882		19960322 (Original)
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1916		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:33259 USPATFULL
 TITLE: Nitrosated and nitrosylated steroids compositions, and methods for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Waltham, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfroe, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197762	B1	20010306
APPLICATION INFO.:	US 1998-157242		19980918 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Desai, Rita		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	16		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)
LINE COUNT: 1841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 1998:128257 USPATFULL
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
INVENTOR(S): Garvey, David S., Dover, MA, United States
Letts, L. Gordon, Dover, MA, United States
Renfro, H. Burt, Wellesley, MA, United States
Richardson, Stewart K., Ashford, CT, United States
PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824669		19981020
APPLICATION INFO.:	US 1996-620882		19960322 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1812		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

Connection closed by remote host

WEST Search History

DATE: Tuesday, February 04, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L9	L8 and mix\$ and coars\$ and fin\$	4	L9
L8	L7 and (COPD or asthma or respiratory)	22	L8
L7	L6 and (um or micrometer or micron?)	22	L7
L6	L5 and (mean particle size)	52	L6
L5	L4 and (glucose or arabinose or lactose or saccharose or maltose or dextrane or sorbitol or mannitol or xylitol or (sodium chloride) or (calcium carbonate))	52	L5
L4	L3 and (average particle size)	62	L4
L3	L2 and (chloride or bromide or iodide or metjhnaesulphonate or paratoluenesulphonate or (methyl sulphate))	71	L3
L2	L1 and Tiotropium	78	L2
L1	inhal\$ and (powder\$ or partic\$ or pellet\$)	33911	L1

END OF SEARCH HISTORY

	Image Doc. Displayed	PT
1	US 20020122826	<input type="checkbox"/>
2	US 20020111495	<input type="checkbox"/>

	Retrieval Classif	Inventor	S	C	P	2	3	4	5
1		Lizio, Rosario et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2		Magee, Thomas Victor et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

	U	1	Document ID	Issue Date	Pages
1	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020122826 A1	20020905	11
2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	US 20020111495 A1	20020815	155

	Title	Current OR	Current XRef
1	Solid peptide preparations for inhalation and their preparation	424/489	241/18
2	Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes	546/291	546/298; 546/315

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS	21	May 27	STN User Update to be held June 7 and June 8 at the SLA 2004 Conference
NEWS	22	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAPLUS
NEWS	23	May 27	CAPLUS super roles and document types searchable in REGISTRY
NEWS	24	May 27	Explore APOLLIT with free connect time in June 2004
NEWS EXPRESS			MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004

=> le caplus uspatful europatful japio medline biosis embase
LE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 16:10:45 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 16:10:45 ON 10 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:10:45 ON 10 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))
L1 60 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))

=> s l1 and (particle# or particulate#)
L2 29 L1 AND (PARTICLE# OR PARTICULATE#)

=> s l2 and powder?
L3 19 L2 AND POWDER?

=> s l3 and capsule?
L4 13 L3 AND CAPSULE?

=> s l4 and (COPD or asthma)
L5 5 L4 AND (COPD OR ASTHMA)

=> s l5 and (method or process) and (making or preparation or manufacture)
6 FILES SEARCHED...
L6 2 L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MANUFACTURE)

=> d l6 1-2 IBIB ABA
'ABA' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in

individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ABS

NO VALID FORMATS ENTERED FOR FILE 'EUROPATFULL'

In a multifile environment, each file must have at least one valid format requested. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):AB

L6 ANSWER 1 OF 2 USPATFULL on STN

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> s

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):L6 ibib ab

MISSING OPERATOR L6 IBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d l6 1-2 IBIB AB

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

L6 ANSWER 2 OF 2 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS
TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.
MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.
MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.
INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP;
YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP
PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, JP
PATENT ASSIGNEE NO: 435424
AGENT: Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675 Muenchen, DE
AGENT NUMBER: 100401
OTHER SOURCE: MEPA2004039 EP 1417975 A1 0322
SOURCE: Wila-EPZ-2004-H20-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PATENT INFORMATION:
PATENT NO KIND DATE

EP 1417975 A1 20040512
'OFFENLEGUNGS' DATE: 20040512
APPLICATION INFO.: EP 2002-747707 20020722

PRIORITY APPLN. INFO.: JP 2001-2001222148 20010723
 JP 2001-2001239895 20010807
 JP 2002-2002056449 20020301
 RELATED DOC. INFO.: WO 02-JP7385 020722 INTAKZ
 WO 2003009872 030206 INTPNR

ABEN A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP.sub4. agonist as an active ingredient. An EP.sub4. agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
 L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)
 L3 19 S L2 AND POWDER?
 L4 13 S L3 AND CAPSULE?
 L5 5 S L4 AND (COPD OR ASTHMA)
 L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

=> d l5 1-5

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:757705 CAPLUS
 DN 139:265796
 TI Preparation of micronized crystalline tiotropium bromide
 monohydrate and formulation as inhalant to treat asthma
 and COPD
 IN Bender, Helmut; Graebner, Hagen; Schindler, Konrad; Trunk, Michael Josef
 Friedrich; Walz, Michael
 PA Boehringer Ingelheim Pharma GmbH & Co. Kg, Germany
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,				
	MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				
	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,				
	NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,				
	ML, MR, NE, SN, TD, TG				
	DE 10212264	A1	20031002	DE 2002-10212264	20020320
	US 2004002510	A1	20040101	US 2003-385175	20030310
PRAI	DE 2002-10212264	A	20020320		
	US 2002-413129P	P	20020924		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:368320 CAPLUS
DN 136:374855
TI Inhalant compositions containing tiotropium salts and
salmeterol salts
IN Schmelzer, Christel; Nagel, Juergen
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE 10056104	A1	20020523	DE 2000-10056104	20001113
	AU 2002027910	A5	20020521	AU 2002-27910	20011109
	EP 1335728	A1	20030820	EP 2001-989446	20011109
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001015226	A	20031007	BR 2001-15226	20011109
	EE 200300228	A	20031015	EE 2003-228	20011109
	JP 2004513146	T2	20040430	JP 2002-540737	20011109
	US 2002193392	A1	20021219	US 2001-54567	20011113
	NO 2003002111	A	20030708	NO 2003-2111	20030512
PRAI	DE 2000-10056104	A	20001113		
	US 2000-251603P	P	20001206		
	WO 2001-EP12962	W	20011109		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:689613 CAPLUS
DN 136:390861
TI Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity
AU Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.
CS Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA
SO Journal of Aerosol Medicine (2001), 14(3), 309-315
CODEN: JAEMEP; ISSN: 0894-2684
PB Mary Ann Liebert, Inc.
DT Journal
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 USPATFULL on STN
AN 2001:75378 USPATFULL
TI Methods and compositions for the prevention of tolerance to medications
IN Ahmed, Tahir, Coral Gables, FL, United States

PA Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

PI US 6235725 B1 20010522

AI US 1999-362540 19990728 (9)

PRAI US 1998-106507P 19981030 (60)

DT Utility

FS Granted

LN.CNT 985

INCL INCLM: 514/056.000

INCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000

NCL NCLM: 514/056.000

NCLS: 514/023.000; 514/053.000; 514/054.000; 514/653.000; 514/826.000

IC [7]

ICM: A61K031-70

EXF 514/53; 514/54; 514/56; 514/653; 514/826; 514/23

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 5 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1417975 EUROPATFULL ED 20040513 EW 200420 FS OS

TIEN REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.

TIDE MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.

TIFR MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.

IN MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP; KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP; KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP; MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun, Osaka 618-8585, JP; YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP; NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP; ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP

PA ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, JP

SO Wila-EPZ-2004-H20-T1b

DS R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R MK; R RO; R SI

PIT EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)

PI EP 1417975 A1 20040512

OD 20040512

AI EP 2002-747707 20020722

PRAI JP 2001-2001222148 20010723

JP 2001-2001239895 20010807

JP 2002-2002056449 20020301

RLI WO 02-JP7385 020722 INTAKZ

WO 2003009872 030206 INTPNR

IC ICM A61K045-00

ICS A61K031-559 C07D207-24 C07D207-27 C07D263-24

C07C405-00 A61P019-08 A61P019-10

=> FIL STNGUIDE
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION

FULL ESTIMATED COST

65.21

65.42

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 4, 2004 (20040604/UP).

=> file caplus uspatful japio europatful biosis embase medline
'EUROPATFUL' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):europatful

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.66

66.08

FILE 'CAPLUS' ENTERED AT 16:28:44 ON 10 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'BIOSIS' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:28:44 ON 10 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:28:44 ON 10 JUN 2004

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
ENTERED AT 16:10:45 ON 10 JUN 2004

L1 60 S INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2 29 S L1 AND (PARTICLE# OR PARTICULATE#)
L3 19 S L2 AND POWDER?
L4 13 S L3 AND CAPSULE?
L5 5 S L4 AND (COPD OR ASTHMA)
L6 2 S L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'
ENTERED AT 16:28:44 ON 10 JUN 2004

=> s l4 1-13

MISSING OPERATOR L4 1-13

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d 14 1-13 ibib abs

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757705 CAPLUS

DOCUMENT NUMBER: 139:265796

TITLE: Preparation of micronized crystalline
tiotropium bromide monohydrate and
formulation as **inhalant** to treat asthma and
COPD

INVENTOR(S): Bender, Helmut; Graebner, Hagen; Schindler, Konrad;
Trunk, Michael Josef Friedrich; Walz, Michael

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078429	A1	20030925	WO 2003-EP2422	20030310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10212264	A1	20031002	DE 2002-10212264	20020320
US 2004002510	A1	20040101	US 2003-385175	20030310
PRIORITY APPLN. INFO.:				
			DE 2002-10212264 A	20020320
			US 2002-413129P P	20020924
AB The invention relates to a micronized crystalline (1alpha, 2beta, 4beta, 5alpha, 7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.0 ^{2,4}]nonane bromide, methods for the production thereof, and the use thereof for producing a medicament, particularly for producing a medicament having an anticholinergic effect. The preparation of tiotropium bromide monohydrate microcrystals includes the solution of tiotropium bromide in water, heating, clarification with active carbon, filtration and slow crystallization followed by micronization in an air jet mill under nitrogen atmospheric and exposing the micronized crystals to water vapor. Parameters of the monocline crystals are given. Micronized crystalline tiotropium bromide monohydrate is formulated to encapsulated inhalation powder and used to treat asthma and COPD. Thus inhalation capsules contained (mg): micronized tiotropium bromide 0.0225; lactose monohydrate (200 M) 5.2025; lactose monohydrate (5 µm) 0.2750; hard gelatin capsules 49.0.				
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:889143 CAPLUS

DOCUMENT NUMBER: 137:358198

TITLE: Stable **powder** inhalation dosage formulation

INVENTOR(S): Etzler, Frank M.

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA

SOURCE: U.S., 6 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482429	B1	20021119	US 2001-885349	20010620
WO 2003000240	A2	20030103	WO 2002-US18406	20020611
WO 2003000240	A3	20030306		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1401409	A2	20040331	EP 2002-732063	20020611
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 2001-885349 A 20010620
WO 2002-US18406 W 20020611

AB An insufflation for the administration of a drug, e.g., ipratropium bromide, albuterol sulfate or **tiotropium bromide**, into a body cavity is described where the carrier for the drug is a finely divided **powder** selected from the group consisting of myoinositol, mannitol and cellobiose. For example, the cellobiose blend with ipratropium bromide which was inhaled from **capsules** into Aerobreather at 20, 40 and 60 L/min has a lower mean **particle** size than the lactose blend, which is the opposite of the **particle** sizing results from the Aerosizer. The peaks of the distributions for the cellobiose blend were shifted to lower **particle** sizes than the lactose blend at all inhalation rates. The difference could reflect differences in adhesion strength, **particle** size distribution or size selection of retained **particles**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:695761 CAPLUS

DOCUMENT NUMBER: 137:237718

TITLE: Inhalant compositions containing anticholinergics and PDE IV inhibitors

INVENTOR(S): Meade, Christopher John Montague; Pairat, Michel; Pieper, Michael Paul

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069945	A2	20020912	WO 2002-EP1988	20020226
WO 2002069945	A3	20030130		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10110772 A1 20020912 DE 2001-10110772 20010307
 EP 1372649 A2 20040102 EP 2002-727329 20020226
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: DE 2001-10110772 A 20010307
 WO 2002-EP1988 W 20020226

OTHER SOURCE(S): MARPAT 137:237718

AB The invention relates to drug compns. based on anticholinergics and PDE IV
 inhibitors, to methods for their production, and to their use as inhalants for
 the treatment of respiratory tract diseases. Thus an inhalation
powder was composed of **capsules** that contained (μ g/
capsule): **tiotropium bromide** 21.7; AWD-12-281
 200; lactose 4778.3.

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:487380 CAPLUS

DOCUMENT NUMBER: 137:68157

TITLE: **Inhalant** compositions containing
 anticholinergics and dopamine agonists

INVENTOR(S): Pairret, Michel; Pieper, Michael Paul; Meade,
 Christopher John Montague

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049624	A2	20020627	WO 2001-EP14568	20011212
WO 2002049624	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10063957	A1	20020627	DE 2000-10063957	20001220
AU 2002035767	A5	20020701	AU 2002-35767	20011212
EP 1345626	A2	20030924	EP 2001-985868	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004516264	T2	20040603	JP 2002-550966	20011212
US 2002122773	A1	20020905	US 2001-27662	20011220
PRIORITY APPLN. INFO.:			DE 2000-10063957 A	20001220
			US 2000-257221P P	20001221
			WO 2001-EP14568 W	20011212

AB The invention relates to novel pharmaceutical compns. based on
 anticholinergic agents and dopamine agonists, a method for the production of
 the compns. and the use of the same for the treatment of respiratory tract
 diseases. Thus an inhalation **powder** contained per
capsule (μ g): **tiotropium bromide** 21.7;
 viozan 270; lactose 4708.3.

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:465799 CAPLUS
DOCUMENT NUMBER: 137:37667
TITLE: **Inhalant** compositions containing
anticholinergics and ciclesonide corticosteroid
INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,
Christopher John Montague
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047668	A2	20020620	WO 2001-EP14579	20011212
WO 2002047668	A3	20020829		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002031691	A5	20020624	AU 2002-31691	20011212
EP 1349549	A2	20031008	EP 2001-991827	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004515528	T2	20040527	JP 2002-549242	20011212
PRIORITY APPLN. INFO.:			DE 2000-10062712 A	20001215
			DE 2000-10054042 A	20001031
			US 2000-253613P P	20001128
			US 2000-257220P P	20001221
			WO 2001-EP14579 W	20011212

AB The invention relates to novel medicament compns. based on anticholinesterase drugs and on ST-126, to methods for their production, and to their use in treating respiratory tract diseases. Thus an inhalation **powder** contained per **capsule** (μ g): **tiotropium bromide** x H₂O 22.5; ciclesonide 250; lactose 4727.5.

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:465798 CAPLUS
DOCUMENT NUMBER: 137:52368
TITLE: **Inhalant** compositions containing
anticholinergics and ST-126 corticosteroid
INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade,
Christopher John Montague
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047667	A2	20020620	WO 2001-EP14567	20011212
WO 2002047667	A3	20021024		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10062712 A1 20020620 DE 2000-10062712 20001215

US 2002183292 A1 20021205 US 2001-86145 20011019

AU 2002024926 A5 20020624 AU 2002-24926 20011212

PRIORITY APPLN. INFO.:

DE 2000-10062712 A 20001215

DE 2000-10054042 A 20001031

US 2000-253613P P 20001128

US 2000-257220P P 20001221

WO 2001-EP14567 W 20011212

AB The invention relates to novel medicament compns. based on
anticholinesterase drugs and on ST-126 corticosteroid, to methods for
their production, and to their use in treating respiratory tract diseases.
Thus an inhalation **powder** contained per **capsule**
(μ g): **tiotropium bromide** x H₂O 22.5; ST-126 250;
lactose 4727.5.

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:368320 CAPLUS

DOCUMENT NUMBER: 136:374855

TITLE: **Inhalant** compositions containing
tiotropium salts and salmeterol salts

INVENTOR(S): Schmelzer, Christel; Nagel, Juergen

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038154	A1	20020516	WO 2001-EP12962	20011109
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056104	A1	20020523	DE 2000-10056104	20001113
AU 2002027910	A5	20020521	AU 2002-27910	20011109
EP 1335728	A1	20030820	EP 2001-989446	20011109
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015226	A	20031007	BR 2001-15226	20011109
EE 200300228	A	20031015	EE 2003-228	20011109
JP 2004513146	T2	20040430	JP 2002-540737	20011109
US 2002193392	A1	20021219	US 2001-54567	20011113
NO 2003002111	A	20030708	NO 2003-2111	20030512

PRIORITY APPLN. INFO.:

DE 2000-10056104 A 20001113

US 2000-251603P P 20001206

WO 2001-EP12962 W 20011109

AB The invention relates to novel drug compns. based on **tiotropium**

salts and on salmeterol salts, a method for their production and their use for treating respiratory conditions. Thus an inhalation **powder** contained per capsule (μg): **tiotropium bromide** 10.8; salmeterol x 1/2 H₂SO₄ 27.9; Lactose 4961.3.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:353268 CAPLUS

DOCUMENT NUMBER: 136:374832

TITLE: Inhalant compositions containing anticholinergics and corticosteroids

INVENTOR(S): Pairet, Michel; Pieper, Michael Paul; Meade, Christopher John Montague; Reichl, Richard; Schmelzer, Christel

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036106	A2	20020510	WO 2001-EP12511	20011023
WO 2002036106	A3	20020919		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10062712	A1	20020620	DE 2000-10062712	20001215
US 2002151541	A1	20021017	US 2001-7182	20011019
US 2002183292	A1	20021205	US 2001-86145	20011019
AU 2002010575	A5	20020515	AU 2002-10575	20011023
EP 1333830	A2	20030813	EP 2001-978463	20011023
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004512359	T2	20040422	JP 2002-538918	20011023
US 2002137764	A1	20020926	US 2001-40196	20011025
US 2003181478	A1	20030925	US 2003-395777	20030324

PRIORITY APPLN. INFO.:

DE 2000-10054042	A	20001031
DE 2000-10062712	A	20001215
US 2000-253613P	P	20001128
US 2000-257220P	P	20001221
DE 2001-10138272	A	20010810
US 2001-314599P	P	20010824
WO 2001-EP12511	W	20011023
US 2001-40196	B1	20011025

AB The invention relates to novel drug compns. based on anticholinergics and corticosteroids, a method for their production and their use for treating respiratory conditions. Thus an inhalation **powder** contained per capsule (μg): **tiotropium bromide** 21.7; budesonide 200; Lactose 4778.3.

L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:689613 CAPLUS

DOCUMENT NUMBER: 136:390861

TITLE: Effective delivery of **particles** with the HandiHaler dry **powder** inhalation system over

a range of chronic obstructive pulmonary disease severity

AUTHOR(S): Chodosh, Sanford; Flanders, Judith S.; Kesten, Steven; Serby, Charles W.; Hochrainer, Dieter; Witek, Theodore J., Jr.

CORPORATE SOURCE: Veterans Administration Outpatient Clinic, Pulmonary Research, Boston, MA, USA

SOURCE: Journal of Aerosol Medicine (2001), 14(3), 309-315
CODEN: JAEMEP; ISSN: 0894-2684

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The HandiHaler is a dry **powder** breath activated inhaler system developed for inhalation therapy for patients with airway disease. Its operation is based on the evacuation of **powder** from a pierced **capsule**. We sought to document the inspiratory flow rates attained by patients inspiring through the HandiHaler with various degrees of airflow limitation. Subjects with stable chronic obstructive pulmonary disease (COPD) were the study's population. An in vitro study of fine **particle** dose was conducted using an Andersen Cascade Impactor to assess medication delivery at low inspiratory flow rates. Subsequently, an in vivo study was conducted to determine inspiratory flow rates in patients with COPD as measured through a pneumotach with a custom coupler device with and without the HandiHaler. Patients were classified into three approx. equal groups of spirometric severity ranging from mild (46-65% predicted normal forced expiratory volume in 1 s [FEV1]), to moderate (28-45%) to severe ($\leq 27\%$). The in vitro study indicated delivery of medication at flow rates as low as 20 L/min. Twenty-six men completed the in vivo study (age 66.9 ± 10.9 yr, FEV1 = 1.02 ± 0.451). The median peak inspiratory flow rates attained in the mild (n = 8), moderate (n = 10), and severe (n = 8) categories were 45, 45.6, and 35.4 L/min resp. The min. peak inspiratory flow rates in the three groups were 28.2, 21.6 and 20.4 L/min. The HandiHaler device effectively delivers **particles** to the lung over a wide range of airflow limitation in patients with COPD.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators.

More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL

TITLE: Supercritical fluid extraction of mould lubricant from hard shell **capsules**

INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States
Saim, Said, New Milford, CT, United States

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled **capsules** and dry, **powdered** pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1417975 EUROPATFULL EW 200420 FS OS

TITLE: REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT.

MITTEL ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT KNOCHENSCHWUND EINHERGEHEN, MIT EP4 AGONIST ALS WIRKSTOFF.

MEDICAMENTS CONTENANT UN AGONISTE DE EP4 EN TANT QUE PRINCIPE ACTIF DESTINES AUX MALADIES ASSOCIEES A UNE PERTE DE LA MASSE OSSEUSE.

INVENTOR(S): MARUYAMA, Toru, c/o Minase Res. Inst., Ono Pharm., Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KOBAYASHI, Kaoru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
KAMBE, Tohru, c/o Minase Res. Inst., Ono Pharm, Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585, JP;
MARUYAMA, Takayuki, c/o Minase Res. Inst., Ono Pha, Co.,

Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Miishima-gun,
 Osaka 618-8585, JP;
 YOSHIDA, Hideyuki, c/o Minase Res Inst, Ono Pharm., Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP;
 NISHIURA, Akio, c/o Minase Res Inst., Ono Pharm, Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP;
 ABE, Nobutaka, c/o Minase Res Inst., Ono Pharm, Co.,
 Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishima-gun,
 Osaka 618-8585, JP
 PATENT ASSIGNEE(S): ONO PHARMACEUTICAL CO., LTD., 1-5, Doshomachi 2-chome,
 Chuo-ku, Osaka-shi, Osaka 541-8526, JP
 PATENT ASSIGNEE NO: 435424
 AGENT: Henkel, Feiler & Haenzel, Moehlstrasse 37, 81675
 Muenchen, DE
 AGENT NUMBER: 100401
 OTHER SOURCE: MEPA2004039 EP 1417975 A1 0322
 SOURCE: Wila-EPZ-2004-H20-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch;
 Verfahren in Englisch
 DESIGNATED STATES: R AT; R BE; R BG; R CH; R CY; R CZ; R DE; R DK; R EE; R
 ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R
 MC; R NL; R PT; R SE; R SK; R TR; R AL; R LT; R LV; R
 MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale
 Anmeldung)
 PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 1417975	A1 20040512
'OFFENLEGUNGS' DATE:		20040512
APPLICATION INFO.:	EP 2002-747707	20020722
PRIORITY APPLN. INFO.:	JP 2001-2001222148	20010723
	JP 2001-2001239895	20010807
	JP 2002-2002056449	20020301
RELATED DOC. INFO.:	WO 02-JP7385	020722 INTAKZ
	WO 2003009872	030206 INTPNR

L4 ANSWER 13 OF 13 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1391200 EUROPATFULL EW 200409 FS OS
 TITLE: DRUG PREPARATIONS.
 ARZNEIMITTEL.
 PREPARATIONS DE MEDICAMENTS.
 INVENTOR(S): ONUKI, Yoichi, 2-31-7, Nakadai, Narita-shi, Chiba
 286-0015, JP;
 OKADA, Minoru, 4-7-20, Kioroshihigashi, Inzai-shi, Chiba
 270-1323, JP;
 SAKAI, Hirotaka, 1-20-6, Yotsukaido, Yotsukaido-shi,
 Chiba 284-0005, JP;
 KANBE, Hideyoshi, 2-21-8, Mama, Ichikawa-shi, Chiba
 272-0826, JP;
 MIZUNO, Hiroyuki, 1-24-19, Hiyoshidai, Tomisato-machi,
 Inba-gun, Chiba 286-0201, JP;
 IMAMORI, Katsumi, 2521-86, Shimoshizushinden,
 Yotsukaido-shi, Chiba 284-0006, JP
 PATENT ASSIGNEE(S): SSP Co., Ltd., 12-4, Nihonbashi-hamacho 2-chome,
 Chuo-ku, Tokyo 103-8481, JP
 PATENT ASSIGNEE NO: 2557581
 AGENT: Hartz, Nikolai, Waechtershaeuser & Hartz,
 Patentanwaelte, Weinstrasse 8, 80333 Muenchen, DE

AGENT NUMBER: 85663
 OTHER SOURCE: MEPA2004017 EP 1391200 A1 0014
 SOURCE: Wila-EPZ-2004-H09-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R TR; R AL; R LT; R LV; R MK; R RO; R SI
 PATENT INFO.PUB.TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG (Internationale Anmeldung)
 PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 1391200	A1	20040225
'OFFENLEGUNGS' DATE:			20040225
APPLICATION INFO.:	EP 2002-726486		20020524
PRIORITY APPLN. INFO.:	JP 2001-2001156853		20010525
RELATED DOC. INFO.:	WO 200JP2005041	020524	INTAKZ
	WO 2002096405	021205	INTPNR

=> d his

(FILE 'HOME' ENTERED AT 16:10:09 ON 10 JUN 2004)

FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
 ENTERED AT 16:10:45 ON 10 JUN 2004

L1	60 S	INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPI
L2	29 S	L1 AND (PARTICLE# OR PARTICULATE#)
L3	19 S	L2 AND POWDER?
L4	13 S	L3 AND CAPSULE?
L5	5 S	L4 AND (COPD OR ASTHMA)
L6	2 S	L5 AND (METHOD OR PROCESS) AND (MAKING OR PREPARATION OR MAN

FILE 'STNGUIDE' ENTERED AT 16:22:26 ON 10 JUN 2004

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, BIOSIS, EMBASE, MEDLINE'
 ENTERED AT 16:28:44 ON 10 JUN 2004

=> file uspatful

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	63.51	129.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

FILE 'USPATFULL' ENTERED AT 16:45:49 ON 10 JUN 2004
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Jun 2004 (20040610/PD)
 FILE LAST UPDATED: 10 Jun 2004 (20040610/ED)
 HIGHEST GRANTED PATENT NUMBER: US6748598
 HIGHEST APPLICATION PUBLICATION NUMBER: US2004111778
 CA INDEXING IS CURRENT THROUGH 10 Jun 2004 (20040610/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Jun 2004 (20040610/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

>>> USPAT2 is now available. USPATFULL contains full text of the	<<<
>>> original, i.e., the earliest published granted patents or	<<<
>>> applications. USPAT2 contains full text of the latest US	<<<
>>> publications, starting in 2001, for the inventions covered in	<<<

```

>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s inhalant and (tiotropium or (tiotropium bromide) or (tiotropium bromide monhydrate))
```

```

1928 INHALANT
236 TIOTROPIUM
236 TIOTROPIUM
145139 BROMIDE
133 TIOTROPIUM BROMIDE
(TIOTROPIUM(W)BROMIDE)
236 TIOTROPIUM
145139 BROMIDE
156 MONHYDRATE
0 TIOTROPIUM BROMIDE MONHYDRATE
(TIOTROPIUM(W)BROMIDE(W)MONHYDRATE)

```

```
L7 13 INHALANT AND (TIOTROPIUM OR (TIOTROPIUM BROMIDE) OR (TIOTROPIUM BROMIDE MONHYDRATE))
```

```
=> s l7 and (particle# or particulate#)
```

```

552872 PARTICLE#
156148 PARTICULATE#

```

```
L8 9 L7 AND (PARTICLE# OR PARTICULATE#)
```

```
=> s l2 and powder?
```

```
437594 POWDER?
```

```
L9 3 L2 AND POWDER?
```

```
=> d l9 1-3 ibib abs
```

```
L9 ANSWER 1 OF 3 USPATFULL on STN
```

```
ACCESSION NUMBER: 2004:132947 USPATFULL
```

```
TITLE: Medical aerosol formulations
```

```
INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL
REPUBLIC OF
Niederlander, Carsten, Riehen, SWITZERLAND
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA,
02205

NUMBER OF CLAIMS: 53

EXEMPLARY CLAIM: 1

LINE COUNT: 986

AB Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.

L9 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL

TITLE: Methods and compositions for the prevention of tolerance to medications

INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL

TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules

INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States

Saim, Said, New Milford, CT, United States

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Page, Thurman K.
 ASSISTANT EXAMINER: Seidleck, Brian K.
 LEGAL REPRESENTATIVE: Raymond, Robert P., Stempel, Alan R., Devlin,
 Mary-Ellen M.
 NUMBER OF CLAIMS: 21
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 24 Drawing Figure(s); 12 Drawing Page(s)
 LINE COUNT: 1487
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Hard shelled capsules and dry, **powdered** pharmaceutical
 formulations are treated with supercritical fluids to remove impurities
 such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 18 1-9 ibib abs

L8 ANSWER 1 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 2004:132947 USPATFULL
 TITLE: Medical aerosol formulations
 INVENTOR(S): Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL
 REPUBLIC OF
 Niederlander, Carsten, Riehen, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101483	A1	20040527
APPLICATION INFO.:	US 2003-473874	A1	20030930 (10)
	WO 2002-CH145		20020311

	NUMBER	DATE
PRIORITY INFORMATION:	CH 2001-60101	20010330
	CH 2001-152701	20010820
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	986	
AB	Calcium salts, magnesium salts and zinc salts of palmitic acid and of stearic acid are suited for use as solid auxiliary agents for medical suspension aerosol formulations based on hydrofluoroalkanes. They improve, in particular, the suspension stability, the mechanical function of the dosing valve, the dosing precision, and the chemical stability of the active substance.	

L8 ANSWER 2 OF 9 USPATFULL on STN
 ACCESSION NUMBER: 2003:283185 USPATFULL
 TITLE: Nitrosated and nitrosylated compounds and compositions
 and their use for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Dover, MA, UNITED STATES
 Letts, L. Gordon, Dover, MA, UNITED STATES
 Renfro, H. Burt, Wellesley, MA, UNITED STATES
 Richardson, Stewart K., Ashford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199529	A1	20031023
APPLICATION INFO.:	US 2003-428936	A1	20030505 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-689851, filed on 13 Oct 2000, GRANTED, Pat. No. US 6579863 Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, GRANTED, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, GRANTED, Pat. No. US 5824669 Division of Ser. No. WO 1997-US4319, filed on 19 Mar 1997, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004

NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 2520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.cndot.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:176162 USPATFULL
TITLE: Medicinal aerosol formulations
INVENTOR(S): Keller, Manfred, Bad Krozingen, GERMANY, FEDERAL REPUBLIC OF
Herzog, Kurt, Basel, SWITZERLAND
Muller-Walz, Rudi, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
Kraus, Holger, Rickenbach, SWITZERLAND
PATENT ASSIGNEE(S): Jago Research AG, MuttENZ, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6585958	B1	20030701
	WO 2000006121		20000210
APPLICATION INFO.:	US 2001-744379		20010413 (9)
	WO 1999-CH337		19990722

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1998-1565	19980724
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Hartley, Michael G.	
ASSISTANT EXAMINER:	Haghighatian, M.	
LEGAL REPRESENTATIVE:	Selitto, Behr & Kim	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	995	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pressure-liquefied propellant mixture for aerosols, comprising

dinitrogen monoxide and a hydrofluoroalkane having 1 to 3 carbon atoms, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, makes possible an improvement in the wetting properties of pharmaceutically active compounds, whereby the formulation problems existing with hydrofluoroalkanes can be overcome with respect to suspension and solution aerosols and thus improved medicinal aerosol formulations can be obtained. With the aid of dinitrogen monoxide, it is also possible to influence the pressure and thus the particle size distribution specifically and, by displacement of oxygen from the hydrofluoroalkanes, to improve the storage stability of oxidation-sensitive active compounds. If desired, the propellant mixture can additionally contain carbon dioxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:161952 USPATFULL
 TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Waltham, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfro, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): Nitromed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6579863	B1	20030617
APPLICATION INFO.:	US 2000-689851		20001013 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-157242, filed on 18 Sep 1998, now patented, Pat. No. US 6197762 Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Badio, Barbara P.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	2028		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO₂ group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO₂ moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO⁺) or nitroxyl (NO⁻), or as the neutral species, nitric oxide (NO) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:75378 USPATFULL
 TITLE: Methods and compositions for the prevention of tolerance to medications
 INVENTOR(S): Ahmed, Tahir, Coral Gables, FL, United States

PATENT ASSIGNEE(S): Baker Norton Pharmaceuticals, Inc., Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235725	B1	20010522
APPLICATION INFO.:	US 1999-362540		19990728 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-106507P	19981030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Levi-Minzi, Simona A.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to β .sub.2 -adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:67205 USPATFULL
TITLE: Supercritical fluid extraction of mould lubricant from hard shell capsules
INVENTOR(S): Horhota, Stephen T., Brookfield, CT, United States
Saim, Said, New Milford, CT, United States
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228394	B1	20010508
APPLICATION INFO.:	US 1998-157267		19980921 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-62099P	19971014 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Seidleck, Brian K.	
LEGAL REPRESENTATIVE:	Raymond, Robert P., Stempel, Alan R., Devlin, Mary-Ellen M.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1487	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hard shelled capsules and dry, powdered pharmaceutical formulations are treated with supercritical fluids to remove impurities such as mold lubricants and moisture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:42141 USPATFULL
 TITLE: Nitrosated and nitrosylated compounds, and compositions and their use for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Dover, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfro, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37116	E1	20010327
	US 5824669		19981020 (Original)
APPLICATION INFO.:	US 1998-219476		19981223 (9)
	US 1996-620882		19960322 (Original)
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1916		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+) or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2001:33259 USPATFULL
 TITLE: Nitrosated and nitrosylated steroids compositions, and methods for treating respiratory disorders
 INVENTOR(S): Garvey, David S., Waltham, MA, United States
 Letts, L. Gordon, Dover, MA, United States
 Renfro, H. Burt, Wellesley, MA, United States
 Richardson, Stewart K., Ashford, CT, United States
 PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197762	B1	20010306
APPLICATION INFO.:	US 1998-157242		19980918 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-620882, filed on 22 Mar 1996, now patented, Pat. No. US 5824669 Continuation of Ser. No. WO 1997-US4319, filed on 19 Mar 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
ASSISTANT EXAMINER:	Desai, Rita		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	16		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 29 Drawing Page(s)
LINE COUNT: 1841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.cndot.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 1998:128257 USPATFULL
TITLE: Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
INVENTOR(S): Garvey, David S., Dover, MA, United States
Letts, L. Gordon, Dover, MA, United States
Renfro, H. Burt, Wellesley, MA, United States
Richardson, Stewart K., Ashford, CT, United States
PATENT ASSIGNEE(S): NitroMed, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824669		19981020
APPLICATION INFO.:	US 1996-620882		19960322 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Hale and Dorr LLP		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 29 Drawing Page(s)		
LINE COUNT:	1812		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are (i) compounds of a steroid, a β -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO.sub.2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO.sub.2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO.sup.+), or nitroxyl (NO.sup.-), or as the neutral species, nitric oxide (NO.circ-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

Connection closed by remote host